Emily Iseman Intern Mentor Program Mount Hebron High School Arthritis Care Specialists of Maryland Mentor: Kathleen Skolnik.

Slides:

Advertisements

Similar presentations

NSAIDs 1 st line of therapy in the medical management of RA.

Advertisements

Drug Therapy for Rheumatoid Arthritis in Adults Prepared for: Agency for Healthcare Research and Quality (AHRQ)

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

The Use of Tocilizumab (Actemra®), an Interleukin-6 receptor antagonist, for the treatment of rheumatoid arthritis in Methotrexate Refractory patients.

Rheumatoid Arthritis “An Autoimmune Mystery” Cynthia Anderson.

SEBs: “What do patients say? Presented by Cheryl L. Koehn 2015 CADTH Symposium Saskatoon, Saskatchewan April 14, 2015.

I MMUNITY : R HEUMATOID A RTHRITIS A C ASE S TUDY Beth Downing, MSN, RN-BC, ONC.

Tena Trbojević Mentor: A. Žmegač Horvat

Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,

All About Rheumatoid Arthritis

Arthritis and Stress… By Jack Schetter The Nature of Arthritis  Occurs within the joint (area where two bones meet)  Inflammation of one or more joints.

Treatment of Rheumatoid Arthritis Then and Now

INFLAMMATION & DEGENERATION ARTHRITIS

Rheumatoid Arthritis in Practice An Expert Commentary With Roy Fleischmann, MD A Clinical Context Report.

Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.

RHEUMATOID ARTHRITIS By: Julie Le and Mary Le 5/2/12 4 th pd.

Rheumatoid Arthritis (RA) By: Leon Richardson Period

1 Mosby items and derived items © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier, Inc. Nursing Management: Arthritis and Connective Tissue Diseases.

Collaboration between Periodontists and Cardiologists

( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.

Dr. M Jokar RA - Definition u Chronic systemic inflammatory disorder u Unknown etiology u Synovium affected u Joint Deformity u Extra-articular.

BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.

Disease modified Anti-rheumatic drugs ( DMARD)

 It is inflammation of one or more of your joints.

Rheumatoid Arthritis Christine Aranyi and Rebecca Boon State university of new york institute of technology Pathophysiolog y Rheumatoid Arthritis (RA)

OSTEOARTHRITIS OF THE KNEE DR. IRA GELB, POTOMAC VALLEY ORTHOPEDICS Kiran Pant, Intern/Mentor Program Mount Hebron High School.

Joint Injuries Arthritis By: Alessandro Iunni, Simon Da Silva, and Dylan Mugford.

A MOVEMENT TO BENEFIT CHILDREN WITH AUTISM Molly Bishop, Mount Hebron High School DEBORAH L. BARROW Orthopaedic and Sports Medicine Center Millersville,

Genetics and Environment: Diabetes - Types 1 and 2 Richy George.

Medical advances that prolong life are generally good Medical treatments these days are worth the costs Radical life extension would be good for society.

Rheumatoid arthritis (RA).  Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally.

Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.

Identifying Early Inflammatory Arthritis

A NEW LOOK AT RA Interactive Hot Topics Series

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Epidemiology of rheumatoid arthritis

My Treatment Approach to Rheumatoid Arthritis

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Drug Therapy of Rheumatoid Arthritis

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

My Treatment Approach to Rheumatoid Arthritis

What’s new in my specialty- Rheumatoid Arthritis

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Epidemiology of rheumatoid arthritis

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Heterogeneity of TCRβ repertoire in autoimmune diseases.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Multivariable model of adjusted

Status of tapering in the first year of follow-up.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.

Presentation transcript:

Emily Iseman Intern Mentor Program Mount Hebron High School Arthritis Care Specialists of Maryland Mentor: Kathleen Skolnik

Upcoming Information  Rheumatoid Arthritis  Treatment Options  Biologic Drugs  Arthritis Care Specialists of Maryland  Surveying the Patients  Conclusions Drawn

Rheumatoid Arthritis  Autoimmune  Pain, swelling, stiffness  Medications: Oral Subdermal Injections Intravenous  ACR 20 20% decrease in swelling 20% decrease in pain & disability

Methotrexate  Liver toxicity  Immune suppressant  Disease Modifying Antirheumatic Drug

Biologic Drugs  Attack the immune system  Animal proteins

Remicade  TNF-inhibitor (TNF attacks healthy tissue)  1 st line of infusions used

Orencia  T cell inhibitor (reduces inflammation, swelling & pain)  2 nd line of infusions used

Actemra  Blocks interleukin 6 (reduces inflammation  3 rd line of infusions used

Arthritis Care Specialists of Maryland  Mentor: Kathleen Skolnik  Priming IV Tubing  Setting up Trays  Monitoring Patient Vitals  Developing Relationships with Patients

Surveying Patients  Gender  Age  Current Biologic  Past Biologics  Methotrexate?  Pain and Mobility  HAQ 20-item Disability Scale

Results - Remicade  Remicade and Methotrexate (18) Average HAQ-.885 HAQ = 0 – 3 Pain improved w/ MTX? - 3 Mobility Improved w/ MTX? - 10  Remicade (12) Average HAQ-.139 HAQ = 0 – 4 Pain improved w/ MTX? - 0 Mobility Improved w/ MTX? - 0

Results - Orencia  Orencia and Methotrexate (4) Average HAQ-.25 HAQ = 0 – 1 Pain improved w/ MTX? - 1 Mobility Improved w/ MTX? - 2  Orencia (1) Average HAQ- n/a HAQ = 0 – n/a Pain improved w/ MTX? – no difference Mobility Improved w/ MTX? – no difference

Results - Actemra  Actemra and Methotrexate (3) Average HAQ HAQ = 0 – 1 Pain improved w/ MTX? - 0 Mobility Improved w/ MTX? - 0  Actemra (2) Average HAQ HAQ = 0 – 0 Pain improved w/ MTX? – no difference (2) Mobility Improved w/ MTX? – no difference (2)

What am I doing with this?  Pamphlet!  Presenting Pamphlet to doctors/nurses at my internship

Conclusion  Methotrexate does not need to be paired with Remicade or Actemra (no difference or better feelings and HAQ), and there was not enough information collected to determine the difference with Orencia

Works Cited  Arthritis Foundation. "Treatment Guides." Arthritis Today. Arthritis Foundation, Web. 11 Dec  Arthritis Foundation. "What Is Rheumatoid Arthritis?" Arthritis Today. Arthritis Foundation, Web. 11 Dec  American College of Rheumatology. "Tocilizumab (Actemra)." American College of Rheumatology. American College of Rheumatology, Mar Web. 21 Nov  Arnett, DK, Bridges, SL, Brown, EE, Danila, MI, Halilova, KI, Hwang, MH, and Morgan, SL. "Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?" International Journal of Rheumatology 2012 (n.d.): n. pag.EBSCOhost. Medline, 9 July Web. 23 Sept  Bingham, Clifton. "Remicade without Methotrexate?" Johns Hopkins Arthritis Center. Johns Hopkins, 26 Sept Web. 18 Dec  Bristol-Myers Squibb. "Indications and Important Safety Information for ORENCIA® (abatacept)." ORENCIA® (abatacept) Official Site. Bristol-Myers Squibb, Sept Web. 13 Nov  "C-Reactive Protein (CRP)." WebMD. WebMD, 18 Mar Web. 16 Oct  Dowshen, Steven. "Blood Test: Comprehensive Metabolic Panel." Kids Health. Nemours, Feb Web. 2 Oct  "Drug-Induced Hepatotoxicity." Drug-Induced Hepatotoxicity. WebMD, n.d. Web. 24 Mar  Genentech. "Proven to Help Relieve Symptoms." ACTEMRA (tocilizumab). Genentech, Web. 06 Nov  George, Stephen W. "Methotrexate at Arthritis Care Specialists of Maryland." Personal interview. 22 Oct  Healthwise. "Complete Blood Count (CBC): Results and Interpretation." WebMD. WebMD, 03 Aug Web. 23 Oct  Jones, G., A. Sebba, J. Gu, M. Lowenstein, A. Calvo, J. Gomez-Reino, D. Siri, M. Tomsic, E. Alecock, T. Woodworth, and M. Genovese. "Comparison of Tocilizumab Monotherapy versus Methotrexate Monotherapy in Patients with Moderate to Severe Rheumatoid Arthritis: The AMBITION Study." Ann Rheum Dis (2010): BMJ Publishing Group Ltd & European League Against Rheumatism, 19 Feb Web.  Jones, Kelly W., and Supen R. Patel. "A Family Physician's Guide to Monitoring Methotrexate." A Family Physicians' Guide to Monitoring Methotrexate. American Family Physician, 1 Oct Web. 25 Sept  Kavanagh, Ronan. "Methotrexate." YouTube. Western Rheumatology, 17 Feb Web. 28 Oct  "Methotrexate (Anti-Rheumatic) Oral." WebMD. WebMD, Web. 09 Oct  "Methotrexate." Livertox. National Library of Medicine, 18 July Web. 25 Sept  "Remicade Medication Guide." Remicade.com. Janssen Biotech, Inc., 29 July Web. 12 Sept  Skolnik, Kate. Personal interview. 2 Oct  Walsh, Nancy. "Methotrexate Not Needed with Actemra in RA." MedPage Today. MedPage Today, 18 Nov Web. 04 Dec